Search

Did You Mean:

Search Results

  • Book
    Sean P. Murphy.
    Summary: Written by an expert in the field with multiple industry certifications, this definitive resource fully addresses information security and privacy considerations and their implications within the business of patient care. The book begins with an overview of the organization, financing, and delivery of healthcare and discusses technology, terminology, and data management principles. The topic coverage continues across all aspects of information security and privacy, with a special emphasis on real-life scenarios in clinical practices and business operations in healthcare. Learn best practices for healthcare information security and privacy with detailed coverage of essential topics such as information governance, roles and occupations, risk assessment and management, incident response, patient rights, and cybersecurity. Written for a global audience, this comprehensive guide addresses U.S. laws and regulations as well as those within the European Union, the United Kingdom, and Canada.--Publisher description.

    Contents:
    Part I: A Healthcare Organization and Information Risk Overview
    Healthcare : organization, technology, and data
    Healthcare : people, roles, and third-party partners
    Healthcare information regulation
    Information risk decision making
    Third-party risk management and promoting awareness
    Information security and privacy events management
    Part II: Healthcare Information Privacy and Security Management
    Information privacy : patient rights and healthcare responsibilities
    Protecting digital health information : cybersecurity fundamentals
    Impact of information privacy and security on health IT
    Workforce competency in healthcare
    Administering risk management and cybersecurity.
    Digital Access AccessMedicine 2015
  • Article
    LeLorier J, DuBreuil-Quidoz S, Lussier-Cacan S, Huang YS, Davignon J.
    Arch Intern Med. 1977 Oct;137(10):1429-34.
    Probucol [4,4-(isopropylidendithio bis)(2,6-di-t-butylphenol)], as as an adjunct to diet, was evaluated for its effect on lowering the plasma cholesterol level in patients with familial hypercholesterolemia (type II). The trial had a double-blind, placebo-controlled, crossover design. About half of the 30 patients responded to a low-cholesterol modified-fat diet with a decrease in the plasma cholesterol level of approximately 13%. When probucol was added to the diet of the responders, their plasma cholesterol level was lowered a further 13%. Patients who did not respond to the diet did show reduced plasma cholesterol concentrations when receiving probucol plus the diet. Analysis of the cholesterol content of the various lipoprotein fractions showed that the low-density lipoproteins accounted for most of the total plasma cholesterol level decrease. There was, as expected, no effect on plasma triglyceride concentrations. Neither the 7-dehydrocholesterol nor the desmosterol level was increased in the plasma of patients treated with probucol for three months. Probucol is useful as an adjunct to diet in lowering plasma cholesterol levels in patients with familial hypercholesterolemia. The drug was well tolerated by all patients.
    Digital Access Access Options